6 active shortage notices across 3 countries.
Last updated 2 Aug 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| United States | high | 2 | 7 Feb 2025 | — | FDA-FE, FDA MedWatch |
| Canada |
| medium |
| 2 |
| 1 Apr 2011 |
| 15 May 2026 |
| HC |
| Italy | medium | 2 | 30 Sept 2025 | — | AIFA |
Clinically related options from Mederti's curated alternatives data. Always confirm suitability with a pharmacist or prescriber before substituting.
Yes. As of the latest regulator updates, Bimatoprost has 6 active shortage notices across 3 countries (United States, Canada, Italy). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Bimatoprost shortages to manufacturing problems, causes not stated by the regulator, regulatory action. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 15 May 2026 to 15 May 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Mederti lists 1 clinically related alternative for Bimatoprost (see the alternatives section above). Alternatives require clinical judgement — always confirm suitability with a pharmacist or prescriber and your national guidance before substituting.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Acetylcholine Chloride · Ach · Dipivefrin Hydrochloride · Dorzolamide · Latanoprost · Apraclonidine (Chlorhydrate D')
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.